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Synthesis and in vitro evaluation of the antitumor
potential and chemo-sensitizing activity of
fluorinated ecdysteroid derivatives†‡
J. Csábi,a A. Martins,§b I. Sinka,c A. Csorba,a J. Molnár,b I. Zupkó,cd G. Tóth,ae
L. M. V. Tillekeratnef and A. Hunyadi*ad
Efflux pumps, like the ABCB1 transporter, play an important role in the chemo-resistance of various tumors
and particularly of cancer stem cells. We have previously reported the chemo-sensitizing activity of apolar
ecdysteroid derivatives on cancer cell lines of various origin and sensitivity to chemotherapeutics. Herein
we report the preparation of three fluorinated derivatives and a dehydrated byproduct from 20-
hydroxyecdysone 2,3;20,22-diacetonide (1) through diethylaminosulfur trifluoride (DAST)-mediated fluori-
nation. Complete NMR assignment of the products is provided. In vitro bioactivity testing was performed
on four human breast cancer cell lines, a neuroblastoma, and a mouse lymphoma cell line and its counter-
part expressing the human ABCB1 efflux transporter. Fluorination increased the ABCB1 inhibitory effect of
the compounds but had little effect on their limited antiproliferative action, which was, however, markedly
increased by a Δ14,15 double bond. Compound 5, a new 14,25-difluoro analog of 1, exerted higher chemo-
sensitizing activity to doxorubicin as compared to its parental compound.
Introduction
Ecdysteroids represent one of the most systematically and ex-
tensively documented family of natural steroids.1 They play
an important hormonal role in regulating development and
reproduction of arthropods. Many plant species can also bio-
synthesize these compounds as a possible defense mecha-
nism against non-adapted phytophagous invertebrates.1,2 The
most abundant ecdysteroid, 20-hydroxyecdysone (20E), repre-
sents the most typical structural features of these compounds:
a cholest-7-en-6-one carbon skeleton (C27) with a cis junction
of the A/B-, and trans junction of the C/D-rings and with sev-
eral hydroxyl groups. Ecdysteroids are known to exert a wide
range of non-hormonal bioactivities in mammals that have
extensively been reviewed.3–5 Our research group has recently
discovered that particularly the less polar ecdysteroids can ex-
ert potent chemo-sensitizing activity on various cancer cell
lines. The studied cell lines included both drug susceptible
(breast: MCF-7, prostate: PC3 and LNCaP, epidermal: KB-3-1
and murine lymphoma: L5178) and multi-drug resistant
(MDR) ones obtained either by transfection with the human
ABCB1 transporter (L5178MDR) or by stepwise adaptation to a
chemotherapeutic agent (MCF-7Dox to doxorubicin, KB-C-1 to
colchicine).6–9 The compounds were identified as weak to
mild inhibitors of ABCB1 function, and this activity was only
marginally correlating with their very strong chemo-
sensitizing activity observed on ABCB1 over-expressing cancer
cells such as L5178MDR.
6,8 Moreover, a less pronounced, but
still significant chemo-sensitization was also observed on can-
cer cell lines with minimal or no detectable ABCB1 expres-
sion, suggesting the involvement of mechanisms other than
the inhibition of efflux pump function.9 Nevertheless, ABCB1
is a potential target particularly in cancer stem cells (CSCs):
over-expression of this transporter is not only an important
mechanism for the chemo-resistance of CSCs,10 but it has
also been found to be closely associated to stem-likeness in
non-small cell lung cancer whose stem-like properties could
be overcome by ABCB1 inhibition.11
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An increasing number of fluorinated antitumor agents are
becoming available for cancer treatment.12 Special properties
of the fluorine atom, such as strong electronegativity, small
size and the low polarizability of the C–F bond, can have
great impact on the biological activity and frequently also on
the metabolic stability of a molecule, and fluorination of nat-
ural products appears to be an increasingly attractive strategy
to obtain new leads for drug discovery.13 Accordingly, our
aim was to prepare fluorinated derivatives of 20E 2,3;20,22-
diacetonide (1), an ecdysteroid with particularly strong
chemo-sensitizing properties, and to investigate related
changes in the antitumor potential as compared to that of
compound 1. Fluorination of this compound was previously
performed in an earlier study by Pascual et al. aiming to
prepare 25-fluoroponasterone A, where the acetonide moieties
served as protecting groups and were eventually removed by
acidic hydrolysis. The 25-fluorinated target compound was
tested in an insect bioassay, and it showed an activity on the
oocyte development of the German cockroach (Blattella
germanica) similar to that of the parental 20E.14 To the best
of our knowledge, however, fluorinated ecdysteroids have
never been reported for their activity on any bioassays related
to mammals.
Results and discussion
Following a two-step purification by column chromatography
and preparative HPLC, four compounds, 2–5 were obtained
from the diethylaminosulfur trifluoride (DAST)-mediated
fluorination reaction of 1. Compounds 2, 3, 4 and 5 gave par-
ent ion [M + H]+ peaks in their ESI-MS spectra at m/z 543,
563, 545, 565, respectively. Appearance of an [M + H–H2O]
+
peak in the MS spectra of 1, 2 and 3 strongly suggested the
presence of at least one remaining hydroxyl group in these
compounds, while such peaks were not visible in case of
compounds 4 and 5, suggesting that these latter two com-
pounds possess no free OH-groups. The 1H and 13C NMR
chemical shifts of the starting compound 1 were in perfect
agreement with literature data.15 The structures of com-
pounds 2–5 were assigned by comprehensive one- and two-
dimensional NMR methods, and by also utilizing the spectra
of compound 1 as reference in addition to those reported
from our recent NMR study on a series of 20E dioxolanes.7
The mass spectrum of compound 2 suggested that the
elimination of a water molecule from 1 took place. This was
confirmed by the NMR spectra indicating the presence of a
Δ14,15 double bond, represented by the appearance of the
chemical shifts of HC-15 (6.08/130.1 ppm) and the quaternary
C-14 (150.4 ppm) observed in the 1H and/or the 13C NMR
spectra. Accordingly, the HMQC spectrum revealed seven
methylene groups, one less than in compound 1, while the
disappearance of a hydrogen atom from position 15 was also
detected in the 1H,1H COSY spectrum leaving only four
members in this structural fragment of correlated protons:
H-15 (6.08 ppm), H2-16 (2.38; 2.63 ppm) and H-17 (2.08
ppm). These assignments were supported by the HMBC spec-
trum. Moreover, C-28 and C-29 showed HMBC cross peaks
with two methyl groups each analogously to the parent com-
pound 1, providing further evidence that the acetonide
groups at position 2,3 and 20,22 remained intact after the re-
action. Hence, compound 2 was identified as Stachysterone B
2,3;20,22-diacetonide.15
In case of compounds 3–5, evidence for fluorine substitu-
tion was found. It is well-known that, as a result of altered
substituent increments, the exchange of an sp3C connected
–OH group to a –F manifests in characteristic changes in the
NMR spectrum. In the α position, namely directly on the
substituted carbon, a ca. 20–25 ppm paramagnetic shift and
in the β position a ca. 2–3 ppm diamagnetic shift can be ob-
served, which effect decreases below 1 ppm in the γ position.
In addition to these, both the 13C and the 1H NMR spectra
show signal splitting caused by the characteristic direct
(∼165 Hz), geminal (22–26 Hz) and vicinal (∼5 Hz) nJĲF,C)
and 3JĲF,H) (4.5 Hz) couplings. Based on these, it could be
evidenced that compounds 3–5 contain a fluorine atom
connected to the C-25, and that compound 5 contains an-
other fluorine substituent also at position C-14. Fluorination
of alcohols catalyzed by DAST can take place through either
SN1 or SN2 reaction mechanism, which also determines the
stereo-specificity of the reaction:16 a priori, the 14-F substitu-
ent in compound 5 can be present in either α or β position.
The latter case would also involve a change of the initially
trans C/D ring junction to cis. The effect of such a configura-
tional change on the 13C chemical shifts can well be esti-
mated by comparing the corresponding chemical shifts of 20-
hydroxyecdysone and its diastereomer 14-epi-20-hydroxy-
ecdysone, where significant, i.e. more than 2 ppm differences
could be detected on the δC-9 (+2.4), δC-12 (+9.2), δC-13
(+4.0), δC-15 (+9.0), δC-16 (+3.2) and δC-17 (+6.2) (our own
unpublished NMR data for 14-epi-20-hydroxyecdysone isolated
from the plant Serratula wolffii17). Considering that no such
changes were detected in case of compound 5, a retained
C-14 configuration can be concluded. Moreover, a detailed
analysis of the NOESY spectrum revealed the steric proximity
of the H3C-18 and the Hβ-15 hydrogen atoms, which is only
possible in case of a trans C/D ring junction, providing fur-
ther evidence for a 14α-F group in compound 5. Accordingly,
the SN1 reaction mechanism is suggested for this substitu-
tion, which mechanism is also more likely whenever steric ef-
fects (e.g. due to a rigid steroid skeleton, as in our case) pre-
vent an SN2 attack.
16 Altogether, compound 5 was identified
as 14-deoxy-14,25-difluoroponasterone A 2,3;20,22-diacetonide,
a new ecdysteroid.
Thanks to the comprehensive one- and two-dimensional
NMR techniques utilized in the structure elucidation process,
a complete signal assignment could be achieved for all com-
pounds including compounds 3 and 4, whose previously pub-
lished NMR data lacked the assignment of several hydrogens,
and certain carbon signals were assigned as interchange-
able.14 The 1H and 13C NMR data of parent compound 1 and
its derivatives 2–5 are compiled in Table 1, structures of the
compounds are shown in Fig. 1.
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Based on previous reports on fluorination reactions using
DAST, it is not surprising, that two kinds of structural modifi-
cations took place in this setting: the OH group in position
14 was either eliminated as in compounds 2 and 4, or
substituted with fluorine as in compound 5. Furthermore,
fluorine substitution of the 25-OH group led to the produc-
tion of compounds 3–5.
Compounds 1–5 were tested for their antiproliferative activ-
ities on a diverse set of tumor cell lines including a panel of
human breast cancer cell lines (MCF-7, T47D, MDA-MB-231
and MDA-MB-361), a human neuroblastoma cell line (SH-
SY5Y), and a murine lymphoma cell line (L5178) and its trans-
fected multi-drug resistant (MDR) counterpart expressing the
human ABCB1 efflux transporter (L5178MDR). The compounds
were also tested for their ability to interfere with the efflux
Table 1 1H- and 13C-NMR shifts of compounds 2–5 as compared to that of compound 1; in ppm, in methanol-d4
Atom no.
1 2 3 4 5
H C H C H C H C H C
1α 1.99 39.0 1.95 38.8 1.97 39.0 1.96 38.8 1.99 38.5
β 1.22 1.24 1.21 1.23 1.27
2 4.27 73.7 4.24 73.5 4.24 73.7 4.23 73.5 4.28 73.6
3 4.30 73.3 4.30 73.4 4.29 73.3 4.28 73.4 4.30 73.1
4α 1.98 27.9 1.83 28.1 1.96 27.8 1.83 28.0 1.93 27.7
β 1.96 1.98 1.96 1.98 1.93
5 2.24 52.7 2.22 52.5 2.22 52.6 2.22 52.5 2.31 52.3
6 — 205.8 — 205.3 — 205.8 — 205.3 — 204.7
7 5.80 122.0 6.06 121.0 5.78 122.0 6.06 121.0 5.92 124.4d 6.5
8 — 167.1 — 158.0 — 167.0 — 158.0 — 159.4d 20.5
9 2.93 35.9 2.54 40.0 2.91 35.9 2.54 40.0 2.76 37.3
10 — 38.9 — 39.7 — 38.9 — 39.7 — 38.8
11α 1.76 21.8 1.81 21.7 1.76 21.7 1.81 21.7 1.84 21.8
β 1.66 1.73 1.64 1.75 1.69
12α 2.10 32.5 1.59 40.7 2.08 32.4 1.58 40.7 1.98 33.0d 4.3
β 1.87 2.25 1.82 2.25 1.98
13 — 48.7 — 48.7 — 48.7 — 48.9 — 49.7da
14 — 85.4 — 150.4 — 85.4 — 150.4 — 108.9d
165.6
15α 1.61 31.8 6.08 130.1 1.59 31.7 6.08 130.1 1.88 29.1d 24.0
β 1.95 1.94 2.13
16α 1.84 22.6 2.38 32.8 1.84 22.6 2.38 32.8 1.86 22.2
β 2.04 2.63 2.02 2.63 2.12
17 2.31 50.6 2.08 59.0 2.27 50.6 2.07 58.9 2.17 51.3
18 0.82 17.8 1.07 20.0 0.80 17.8 1.07 20.0 0.86 17.1d 3.5
19 0.96 24.2 0.94 23.8 0.95 24.2 0.94 23.8 1.00 22.6
20 — 86.0 — 84.8 — 85.9 — 84.8 — 85.3
21 1.18 22.8 1.21 22.0 1.15 22.8 1.21 22.0 1.19 24.2
22 3.69 83.5 3.74 83.2 3.68 83.0 3.76 82.7 3.71 82.8
23 1.52 24.9 1.56 24.9 1.52 24.5d 1.491.56 24.6d 4.5 1.53 24.5d 4.5
1.51 1.49 1.51 5.1 1.53
24 1.49 42.4 1.46 42.1 1.61 40.2d 1.63 39.9d 1.63 40.0d 23.1
1.73 1.70 1.86 22.9 1.85 22.5 1.87
25 — 71.3 — 71.2 — 96.5d — 96.6d — 96.0d 166.0
164.9 164.9
26 1.20 29.1 1.17 29.0 1.34 26.8d 1.35 26.7d 1.33 26.8d 24.8
24.5 24.9
27 1.21 29.0 1.19 29.7 1.31 27.4d 1.31 27.5d 1.36 27.3d 24.7
24.4 24.4
28 — 109.6 — 109.6 — 109.6 — 109.6 — 109.6
29 — 108.2 — 108.2 — 108.3 — 108.3 — 108.4
iPr-(2,3) β 1.47 29.0 1.45 28.9 1.45 29.0 1.45 28.9 1.47 29.0
iPr-(2,3) α 1.32 26.8 1.30 26.7 1.30 26.8 1.30 26.8 1.31 26.7
iPr-(20,22) β 1.32 27.3 1.28 27.3 1.30 27.3 1.28 27.3 1.32 27.2
iPr-(20,22) α 1.39 29.5 1.38 29.4 1.37 29.5 1.39 29.4 1.40 29.4
a In case of compounds 3–5 the symbol “d” after the 13C chemical shifts indicates doublet splitting (Hz) resulted from 1JĲF,C), 2JĲF,C) or 3JĲF,C)
coupling. On signal C-13 in compound 5, due to overlapping with the strong solvent signal, the determination of 3JĲF,C) failed.
Fig. 1 The structures of compounds 1–5.
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function of ABCB1 on the L5178MDR cell line, as determined by
means of the intracellular accumulation of rhodamine 123, a
well-known ABCB1 substrate fluorescent dye; results of these
studies are compiled in Table 2. In general, fluorine substitu-
tion at C-25 or C-14 and C-25 appears to have little effect on
the very mild antiproliferative activity of compound 1, as seen
from a comparison of the results obtained for compounds 1, 3
and 5. Moreover, a comparison of the activities of compounds
2 and 4 leads to the same conclusion. On the other hand, a
Δ14,15 double bond, formed by the elimination of the 14-OH
group, markedly increased the antiproliferative activity of com-
pounds 2 and 4, as compared to compounds 1 and 3, respec-
tively. It is worth noting that, even though all of the above
structural changes led to more lipophilic compounds, their ac-
tivity did not show any correlation to the logp values, which
were calculated as 4.01, 4.61, 4.91, 5.50 and 5.80 for com-
pounds 1–5 by using ChemAxon's web based resource
available at http://chemicalize.org.18 The most relevant cell
line specific differences in the antiproliferative potential
of the compounds were observed between the MCF-7 and
T47D cells. Although receptorial status (i.e. expression of es-
trogenic and progestin receptors) of these two cell lines is sim-
ilar, the expression levels of steroid metabolizing enzymes are
substantially different.19 Interestingly, an approximately
3-times selectivity towards T47D over MCF-7 cells was ob-
served in case of compounds with a Δ14,15 double bond (com-
pounds 2 and 4) or a 14-F moiety (compound 5), which selec-
tivity was not present for neither of the two 14-
hydroxyecdysteroids (compounds 1 and 3). Moreover, both the
fluorination (at either position) and the 14-OH elimination
manifested in a significant increase in the ABCB1 inhibitory
activity, as compared to the parental compound 1, particularly
when both a Δ14,15 double bond and a 25-fluoride group was
present as in compound 4. Concerning the chemical changes
at C-14, it might be worth noting that dehydroxylation at this
position is among the known primary metabolic conversions
of ecdysteroids in mammals.3,20 Accordingly, one could also
expect a higher metabolic stability for 14-fluorinated (5) or
dehydrated compounds (2 and 4) as compared to that of the
14-hydroxyecdysteroids 1 and 3; this should certainly be clari-
fied by future studies.
Following the above observations, our next aim was to test
the effect of these structural and bioactivity changes on the
chemo-sensitizing properties of compound 1. Accordingly,
the antiproliferative activity of all compounds was tested in
combination with doxorubicin on the mouse lymphoma cell
line pair, by using the checkerboard microplate method and
calculating combination index (CI) values to characterize and
quantify the interaction between the two drugs.21 Results of
this study are compiled in Table 3.
Considering that in case of chemotherapy the desirable
outcome is a complete eradication of the tumor, a weighted
average CI value (where CIs at higher inhibition rates count
more) has been suggested as an important measure for the
relevance of synergism or antagonism on cancer cell lines.21
As compared to compound 1 that acted in strong synergism
with doxorubicin, the more cytotoxic dienone compounds 2
and 4 exerted a much less profound chemo-sensitizing activ-
ity on both cell lines. This is particularly interesting in view
of their high ABCB1 inhibitory activity, providing further evi-
dence to our previous assumption that a functional efflux
pump inhibition is unlikely to be the key mechanism for
chemo-sensitization by ecdysteroids.6,9 A 25-fluoro substitu-
tion had a small, but rather weakening effect on the chemo-
sensitizing activity as compared to the corresponding 25-
hydroxyecdysteroids. On the other hand, the 14,25-
difluorinated compound 5 showed a stronger synergism with
doxorubicin as compared to the parental compound 1 in par-
ticularly on the non-MDR cell line L5178. Structure–activity
relationships observed in our studies are summarized in
Fig. 2.
Experimental
General information
20-Hydroxyecdysone 2,3;20,22-diacetonide (1) was s0before;6
briefly, 20E was reacted with acetone in the presence of
phosphomolybdic acid as catalyst. Reverse phase HPLC was
performed on a system of two Jasco PU-2080 pumps
connected to a Jasco MD-2010 Plus photodiode-array detector
(Jasco Co., Tokyo, Japan), by utilizing Kinetex XB-C18 analyti-
cal (250 × 4.6 mm, 5 μm; 80% aqueous acetonitrile, 0.8 mL
min−1) or preparative (250 × 21.2 mm, 5 μm; 90% aqueous
acetonitrile, 10.0 mL min−1) columns. Retention times for the
analytical system are given below (see compound characteri-
zation data). Mass spectra were recorded on an API 2000
Table 2 Antiproliferative and ABCB1 inhibitory activities of compounds 1–5. Calculated IC50 values are given in mean ± SEM, n = 2–5, number of repli-
cates are given in the table. C: cisplatin, D: doxorubicin. FAR: fluorescent activity ratio; FAR = (FLMDR
treated/FLMDR
untreated), where FL is the mean of the
fluorescence. Positive control: 20 μM of verapamil, FAR = 6.46
IC50 (μM) FAR
MCF-7 (n) T47D (n) MDA-MB-231 (n) MDA-MB-361 (n) SH-SY5Y (n) L5178 (n) L5178MDR (n) 2 μM 20 μM
1 75.1 ± 3.4 (5) 84.7 ± 3.9 (5) 106.1 ± 7.2 (4) 69.2 ± 6.0 (4) 126.8 ± 9.8 (3) 82.9 ± 1.0 (2) 106.1 ± 3.3 (2) 3.33 11.28
2 30.1 ± 0.8 (5) 10.9 ± 0.3 (5) 38.53 ± 3.8 (5) 13.8 ± 0.4 (5) 20.8 ± 0.3 (3) 14.6 ± 0.3 (3) 19.3 ± 0.5 (3) 1.28 57.36
3 63.1 ± 2.3 (5) 70.3 ± 1.3 (5) 48.85 ± 2.0 (5) 30.9 ± 2.6 (4) 70.7 ± 4.1 (3) 48.3 ± 0.2 (3) 50.1 ± 2.1 (3) 1.59 38.62
4 43.8 ± 1.7 (4) 17.4 ± 1.0 (5) 50.18 ± 2.6 (5) 11.8 ± 1.2 (5) 18.8 ± 1.2 (3) 14.1 ± 0.8 (3) 17.4 ± 1.2 (3) 31.15 109.37
5 127.5 ± 4.3 (5) 49.2 ± 5.0 (5) 98.43 ± 17.2 (4) 53.8 ± 5.7 (5) 125.6 ± 13.2 (2) 88.6 ± 1.1 (2) 82.3 ± 1.4 (3) 11.02 89.78
C 5.8 ± 0.3 (5) 9.8 ± 1.0 (5) 19.1 ± 1.8 (5) 3.7 ± 0.5 (5) — — — — —
D — — — — 0.14 ± 0.02 (3) 0.23 ± 0.01 (3) 3.54 ± 0.44 (3) — —
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triple quadrupole tandem mass spectrometer (AB SCIEX, Fos-
ter City, CA, USA) in positive mode with an electrospray ion
source (ESI).
Synthetic procedure
120 mg (0.214 mmol) of compound 1 was dissolved in 3 mL
of anhydrous methylene chloride (Acros Organics, New Jer-
sey, USA) at −78 °C under nitrogen atmosphere. 34 μL (1.2
equiv.) of (diethylamino)sulphur-triflouride (DAST, Acros Or-
ganics, New Jersey, USA) was added, and the reaction mixture
was stirred at room temperature for 75 minutes. On comple-
tion, the mixture was quenched with 5% aqueous solution of
NaHCO3 (Fisher Scientific, Pittsburgh, PA, USA), then the
mixture was extracted with methylene chloride (Pharmaco-
Aaper, USA). The combined organic layers were dried with
anhydrous Na2SO4 (Fisher Scientific, Pittsburgh, PA, USA), fil-
tered and evaporated in vacuo. Column chromatography on
silica was applied using a gradient of n-hexane (Sigma-Al-
drich, USA) and ethyl acetate (Pharmaco-Aaper, USA) with the
following steps: 8 : 2, 7.5 : 2.5, 7 : 3, 6.5 : 3.5, 6 : 4 and 4 : 6, v/v
each. Ten fractions of 10 mL were collected with each compo-
sition, and the combined fractions 8–9, 10–13, 16–22 and 41–
55 contained compounds 5, 4, 3 and 2, respectively. Final pu-
rification was performed by preparative HPLC as described
above, and the isolated yields were as follows: 2 (41 mg,
35.3%), 3 (20 mg, 16.6%), 4 (20 mg, 17.2%), 5 (4 mg, 3.3%).
NMR spectroscopy
1H (600 MHz) and 13C (150 MHz) NMR spectra were recorded
at room temperature on a Bruker Avance III 600 MHz spectro-
meter equipped with a cryo probehead. Amounts of approxi-
mately 1–10 mg of compounds 1–5 were dissolved in 0.6 mL
Table 3 Combination index (CI) values at 50%, 75% and 90% of inhibition for compounds 1–5 combined with doxorubicin on the ABCB1 transfected
L5178MDR and parental L5178 cell lines. 0 < CI < 1, CI = 1 and CI > 1 represent synergism, additivity and antagonism, respectively. Dm,m, and r represent
antilog of the x-intercept (activity), slope (shape of the dose–effect curve), and linear correlation coefficient (conformity of the data) of the median-
effect plot, respectively.21 CIavg = (CI50 + 2 × CI75 + 3 × CI90)/6
Cell line
Drug
ratioa
CI values at
Dm m r CIavgED50 ED75 ED90
1 L5178MDR 10.2 : 1 0.31 0.18 0.11 8.926 1.902 0.937 0.17 (ref. 6)
20.4 : 1 0.27 0.14 0.07 11.678 3.246 0.964 0.13 (ref. 6)
81.5 : 1 0.39 0.22 0.12 26.598 3.859 0.970 0.20 (ref. 6)
L5178 81.5 : 1 0.74 0.71 0.68 6.742 1.614 0.933 0.70
163 : 1 0.67 0.55 0.46 11.236 2.103 0.942 0.53
326 : 1 0.61 0.55 0.51 17.795 1.872 0.945 0.54
2 L5178MDR 10.2 : 1 0.55 0.45 0.39 7.300 2.460 0.992 0.44
20.4 : 1 0.54 0.44 0.37 8.338 2.905 0.989 0.42
81.5 : 1 1.09 0.87 0.69 19.144 3.664 0.985 0.82
L5178 81.5 : 1 0.99 0.89 0.82 9.506 2.300 0.982 0.87
163 : 1 0.93 0.89 0.86 11.103 2.244 0.970 0.88
326 : 1 0.90 0.81 0.73 12.112 2.720 0.991 0.78
3 L5178MDR 10.2 : 1 0.19 0.17 0.16 4.617 2.646 0.999 0.17
20.4 : 1 0.19 0.19 0.19 5.760 2.468 0.908 0.19
81.5 : 1 0.35 0.33 0.33 13.551 3.436 0.938 0.33
L5178 81.5 : 1 0.80 0.66 0.56 9.945 2.675 0.982 0.63
163 : 1 0.85 0.76 0.71 15.042 2.488 0.978 0.75
326 : 1 1.04 0.96 0.91 23.554 2.696 0.981 0.95
4 L5178MDR 10.2 : 1 0.56 0.34 0.22 9.059 5.479 1.000 0.32
20.4 : 1 0.48 0.36 0.28 9.620 3.338 0.983 0.34
81.5 : 1 0.78 0.73 0.69 19.112 2.281 0.935 0.72
L5178 81.5 : 1 0.73 0.80 0.89 6.893 2.560 0.965 0.83
163 : 1 0.80 0.87 0.95 8.861 2.850 0.987 0.90
326 : 1 0.79 0.84 0.90 9.569 3.217 0.993 0.86
5 L5178MDR 10.2 : 1 0.23 0.11 0.06 5.904 4.546 0.948 0.10
20.4 : 1 0.21 0.12 0.07 7.733 3.375 0.957 0.11
81.5 : 1 0.24 0.16 0.11 13.888 3.040 0.966 0.15
L5178 81.5 : 1 0.70 0.42 0.27 6.822 2.765 0.990 0.39
163 : 1 0.60 0.44 0.34 9.757 2.248 0.944 0.42
326 : 1 0.72 0.59 0.52 17.179 2.134 0.990 0.58
a Molar drug ratios are given; serial dilutions of doxorubicin were initiated from a commercially available injection of 2 mg mL−1 (doxorubicin
hydrochloride, Teva).
Fig. 2 Structure–activity relationships observed for substituents at
C-14 (R1) and C-25 (R2).
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of methanol-d4 and transferred to 5.0 mm Norell XR-55-7
NMR sample tubes. Chemical shifts are given on the δ-scale
and are referenced to the solvent (methanol-d4: δC = 49.1 and
δH = 3.31 ppm). Pulse programs of all experiments (
1H, 13C,
HMQC, COSY, HMBC and NOESY) were taken from the
Bruker TopSpin 3.1pl5 software library.
Compound characterization data
Stachysterone B 2,3;20,22-diacetonide (2) (ref. 22). Yellow
crystals (41 mg, 35.3%; HPLC Rt = 6.92 min; purity at λ = 299 nm:
90.4 %); m.p. 219–220 °C; ESI-MS: 563 [M + H]+, 545 [M + H–
H2O]
+, 485 [M + H–H2O–C3H5F]
+; for 1H- and 13C-NMR data,
see Table 1.
25-Fluoroponasterone A 2,3;20,22-diacetonide (3) (ref. 14).
White crystals (20 mg, 16.6%; HPLC Rt = 9.53 min; purity at
λ = 243 nm: 96.0 %); m.p. 106–108 °C; ESI-MS: 543 [M + H]+,
525 [M + H–H2O]
+, 467 [M + H–H2O–C3H6O]
+; for 1H- and
13C-NMR data, see Table 1.
14-Deoxy-14,15-didehydro-25-fluoroponasterone A 2,3;20,22-
diacetonide (4) (ref. 14). White crystals (20 mg, 17.2%; HPLC
Rt = 13.31 min; purity at λ = 297 nm: 99.3%); 208–209 °C;
ESI-MS: 545 [M + H]+, 487 [M + H–C3H6O]
+, 469 [M + H–
C3H6O–H2O]
+; for 1H- and 13C-NMR data, see Table 1.
14-Deoxy-14,25-difluoroponasterone A 2,3;20,22-diacetonide
(5). Amorphous solid (4 mg, 3.3%; HPLC Rt = 13.49 min;
purity at λ = 239 nm: 99.5%); ESI-MS: 565 [M + H]+, 507 [M +
H–C3H6O]
+; for 1H- and 13C-NMR data, see Table 1.
Cancer cell lines
Breast cancer (MCF-7, MDA-MB-231, MDA-MB-361 and T47D),
neuroblastoma (SH-SY5Y) and mouse T-cell lymphoma
(L5178) cell lines were purchased from the European Collec-
tion of Cell Cultures (ECCAC, Salisbury, UK). L5178MDR cell
line was obtained by transfecting L5178 cells with pHa
MDR1/A retrovirus,23 and it was selected by culturing the
infected cells with 60 μg L−1 colchicine. Breast cancer cells
were cultured in minimal essential medium (MEM)
supplemented with 10% fetal bovine serum (FBS), 1% non-
essential amino acids and antibiotic–antimycotic mixture.
SH-SY5Y neuroblastoma cells were cultured in MEM
supplemented with non-essential amino acids, 1 mM Na-py-
ruvate, 10% FBS, nystatin, 2 mM L-glutamine, 100U penicillin,
and 0.1 mg streptomycin. L5178 and L5178MDR cells were
cultured in McCoy's 5A medium supplemented with 10%
heat inactivated horse serum, L-glutamine, and antibiotics
(penicillin and streptomycin). All cell lines were cultured at
37 °C in humidified air containing 5% CO2. Media and sup-
plements were purchased from Lonza Group Ltd., (Basel,
Switzerland), Difco (Detroit, MI, USA) or Sigma.
Cytotoxicity assay
The antiproliferative actions of the prepared compounds were
determined by means of MTT assay.24 Briefly, near-confluent
cancer cells were seeded onto a 96-well microplate at the den-
sity of 5000 cells per well except for MDA-MB-361 and SH-
SY5Y, which were seeded at 10 000 per well. After overnight
preincubation, 200 μL new medium, containing the tested
compounds in the concentration range of 1–150 μM, was
added. With respect to the non-adherent mouse lymphoma
cell lines, 6 × 103 cells were added to each well containing
McCoy's 5A medium and compounds at the same concentra-
tion range as mentioned above. After incubation for 72 h (48
h in case of SH-SY5Y cells), the viability of the cells was
assayed by the addition of 20 μL of 5 mg ml−1 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
solution. MTT was metabolized by intact mitochondrial re-
ductase and precipitated as purple crystals during a 4 h con-
tact period. The medium was next removed and the precipi-
tated formazan crystals were dissolved in 100 μL of DMSO
during a 60 min period of shaking at 37 °C. Finally, the re-
duced MTT was assayed at 545 nm, using a microplate
reader; wells with untreated cells served as control. IC50
values, referring to the concentration of compound exerting
50% growth inhibition, were calculated by nonlinear regres-
sion utilizing the logĲinhibitor) vs. normalized response (vari-
able slope) curve fitting model of GraphPad Prism 5.0 with
an ordinary fit. Two experiments were performed with 5 par-
allel wells.
ABCB1 inhibition assay
Inhibition of ABCB1 function was investigated through the
intracellular retention of rhodamine 123, a fluorescent dye,
evaluated by flow cytometry.6 Briefly, 2 × 106 cells per mL
were treated with 2 or 20 μM of each compound. After 10 min
incubation, rhodamine 123 (Sigma) was added to a final con-
centration of 5.2 μM and the samples were incubated at 37
°C in water bath for 20 min. Samples were centrifuged (2000
rpm, 2 min) and washed twice with phosphate buffer saline
(PBS, Sigma). The samples were re-suspended in 0.5 mL of
PBS and their fluorescence was measured with a Partec
CyFlow flow cytometer (Partec, Münster, Germany). 20 μM of
verapamil (Sanofi-Synthelabo, Budapest, Hungary) was used
as positive control.
Combination assay
The combined activity of doxorubicin (Teva, Hungary) and
ecdysteroids was determined using the checkerboard micro-
plate method as published before.6 Briefly, cell suspension
(10 000 cells per well) was incubated with doxorubicin and
the compound to be tested for 48 h at 37 °C under 5% CO2.
Cell growth rate was determined through MTT staining, as
described above. The interaction was evaluated by using the
CompuSyn software (CompuSyn, Inc, USA) for the constant
ratios and combination index (CI) values are presented for
50, 75 and 90% of growth inhibition.
Conclusions
In the present study, four compounds have been prepared
from a DAST-mediated fluorination of 20-hydroxyecdysone
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2,3;20,22-diacetonide (1), a previously identified chemo-
sensitizer agent. Water elimination at C-14, as well as fluo-
ride substitution at C-25 and/or C-14 took place during the
reaction, leading to one new (5) and three known (2–4)
ecdysteroids. NMR assignments of the known compounds
have been completed herein. None of the obtained com-
pounds have previously been studied for their antitumor
properties, and valuable new structure–activity relationships
were revealed concerning the ABCB1 inhibition, anti-
proliferative and chemo-sensitizing activity of ecdysteroid
derivatives.
Considering the major importance of the ABCB1 efflux
pump in the chemo-resistance and stem-likeness of cancer
stem cells,10,11 compounds that can sensitize ABCB1 over-
expressing cancer cells to chemotherapeutics are of potential
interest to the CSC paradigm. Based on its highly potent
chemo-sensitizing activity on the mouse lymphoma cell line
pair, compound 5, a new 14,25-difluorinated derivative of 1,
is particularly promising in this regard; further studies are
planned to investigate its potential use in the eradication of
cancer stem cells.
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